Relmada Therapeutics, Inc. · HAM:4E2

Relmada Therapeutics, Inc. financial statements

Relmada Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Revenue0000000
Cost of revenue1.26K3.75K4.87K2.63K
Gross profit-1.26K-3.75K-4.87K-2.63K
Research and development26.9M46.2M54.8M113.3M90.6M36.0M7.86M7.02M2.94M2.94M
Selling, general and administrative311.9K37.7M48.9M47.9M35.1M24.9M7.25M3.98M
Operating income-59.1M-83.9M-103.7M-161.2M-125.7M-60.8M-15.1M-12.7M-6.92M-6.92M
Depreciation and amortization83.9M103.7M2.00K1.26K3.75K4.36K4.87K2.63K2.63K
EBITDA-36-293-161.2M-125.7M-60.8M-15.1M-12.7M-6.91M-6.91M
Interest expense4.21M48.3K1.40M1.34M
Income before tax-57.4M-80.0M-98.8M-157.0M-125.8M-59.5M-15.0M-8.96M
Income tax-103.7K-2.66M48.3K-1.38M4.59M2.05M
Net income-57.4M-80.0M-98.8M-157.0M-125.8M-59.5M-15.0M-17.3M-8.96M-8.96M
Earnings per share, basic-1.45-2.65-3.28-5.30-7.16-3.81-1.62-2.74-2.86-2.86
Earnings per share, diluted-1.45-2.65-3.28-5.30-7.16-3.81-1.62-2.74-2.86

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Cash and equivalents3.50M3.86M4.09M5.40M44.4M2.50M36.3M9.22M2.24M2.24M
Short-term investments89.5M41.1M92.2M142.9M167.5M114.6M80.2M
Receivables512.4K86.4K79.5K73.1K72.1K
Inventory4.04M11.3M903.2K459.0K426.9K
Current assets94.0M45.8M97.5M152.9M223.3M118.1M116.9M9.98M2.74M2.74M
Property, plant and equipment1.26K5.01K7.21K7.21K12.1K
Total assets94.0M45.8M97.6M152.9M223.3M118.2M117.1M10.2M3.05M3.05M
Accounts payable1.57M4.13M3.51M5.26M11.2M8.35M522.7K924.4K765.4K765.4K
Current liabilities6.43M10.3M12.2M12.5M15.1M12.6M1.46M2.61M5.90M5.90M
Total debt110.2K2.94M
Total liabilities7.49M10.3M12.2M12.5M15.1M12.6M1.46M2.61M8.56M8.56M
Shareholders' equity86.5M35.5M85.4M140.4M208.3M105.6M115.7M7.61M-5.51M-5.51M
Shares outstanding73.3M30.2M30.1M30.1M27.7M16.3M14.5M9.74M3.14M3.14M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY2018
Cash from operations-45.8M-51.8M-51.7M-103.8M-91.9M-27.8M-12.1M-10.5M-6.00M-6.00M
Capital spending00-4-3-5-182.1M-84.8M-12.4K-12.4K
Free cash flow-45.8M-51.8M-51.7M-103.8M-91.9M-209.9M-96.9M-6.01M-6.01M
Cash from investing-48.1M51.6M50.5M19.7M-54.1M-34.4M-80.2M-12.4K-12.4K
Cash from financing93.6M-40.3K-98.5K45.0M187.9M28.5M126.1M17.5M6.54M6.54M
Share buybacks42.7M113.9M17.8M
Change in cash-360.5K-234.5K-1.30M-39.0M41.9M-33.8M33.9M6.98M528.4K528.4K